JP Morgan raises Halozyme price target to $78
JP Morgan increased its Halozyme Therapeutics price target to $78.00 per share from $70.00, according to ratings actions cited by Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.